Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Specialty S.A. (GSSA) has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co (Hansoh Pharma) for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC).
Under the terms of the agreement, Glenmark receives exclusive rights to develop and commercialize Aumolertinib across its licensed territories: Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the agreement. Hansoh Pharma will receive an upfront payment of low double-digit million USD, followed by potential regulatory and commercial milestone payments possibly cumulating to over $1 billion, in addition to tiered royalties on net sales in the licensed territories.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
